FDA replaces Women’s Health director

Share this article:
The FDA named Theresa Toigo acting director of its Office of Women's Health (OWH).
She replaces Susan Wood, who quit this month in protest after the agency refused to permit OTC sales of Barr's Plan B emergency contraceptive.
Toigo is an FDA veteran who also heads the agency's Office of Special Health Issues.
The FDA will conduct a search for a permanent replacement, an FDA spokeswoman told MM&M, although a timeframe for finding a permanent OWH director is not being given.
Dr. Lester Crawford, FDA commissioner, announced Toigo's appointment Friday.
Crawford's own confirmation had been held up by Senate Democrats until the administration set a Sept. 1 deadline for FDA to make a decision on Plan B. On Aug. 26, however, Crawford ordered a 60-day public comment period on Plan B, saying the regulatory and policy issues raised by Barr's application -- i.e., whether Plan B can switch to OTC status for women ages 16 and older and remain Rx status for women under 16 -- were too weighty to be decided behind closed doors.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.